A study looked at more than 23,600 Medicare beneficiaries with RA who had received a ≥30-day prescription of an opioid drug. Participants were grouped according to those who had been prescribed a ...

A cross-sectional study finds that patients with rheumatoid arthritis receiving disease-modifying antirheumatic drugs (DMARDs) exhibit a reduced immune response to the COVID-19 vaccine compared with ...

Please provide your email address to receive an email when new articles are posted on . JAK inhibition carried higher malignancy risk vs. biologic DMARDs. Malignancy risk was seen in older patients ...

Since their first publication in 2010, the EULAR recommendations for the use of disease-modifying anti-rheumatic treatments (DMARDs) in people with RA have become a most important publication in the ...

While overall risks for adverse birth outcomes were not increased in children born to fathers who used disease-modifying antirheumatic drugs (DMARDs), such as methotrexate, for autoimmune diseases in ...

How long do you need to take a disease-modifying antirheumatic drug (DMARD) for rheumatoid arthritis before it's fully effective? It depends on which one you use. But they all take a while, says Eric ...

Treatment with biologic DMARDs vs standard therapy improved clinical response rates and flare outcomes among patients with polyarticular JIA.

Biologic vs conventional DMARDs may offer cardioprotective benefits among patients with PsA, though an increased risk for infection requires vigilance.